Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

Conclusions: This is the first documentation of vessel co-option as a mechanism of acquired resistance to anti-angiogenic therapy and could have important implications including the potential therapeutic benefits of targeting vessel co-option in conjunction with vascular endothelial growth factor receptor signaling.

Source: JNCI - April 7, 2016 Category: Cancer & Oncology Authors: Kuczynski, E. A., Yin, M., Bar-Zion, A., Lee, C. R., Butz, H., Man, S., Daley, F., Vermeulen, P. B., Yousef, G. M., Foster, F. S., Reynolds, A. R., Kerbel, R. S. Tags: Article Source Type: research